Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Johnson & Johnson (NYSE: JNJ) faces significant challenges in its third attempt to use the 'Texas Two-Step' bankruptcy strategy to manage talc-related liabilities. The U.S. Court of Appeals for the 3rd Circuit recently rejected J&J's previous bankruptcy attempt, deeming it filed in bad faith. Additionally, bipartisan legislation, the Ending Corporate Bankruptcy Abuse Act (ECBA) of 2024, has been introduced to ban such maneuvers.
J&J faces a July 26 deadline for talc claimants to vote on a third bankruptcy attempt. Critics argue the proposed compensation unfairly shortchanges victims. The company needs 75% approval to proceed with another Texas Two-Step filing in Texas. Lawyers representing ovarian cancer victims urge J&J to abandon this strategy and provide fair compensation.
Today at 5pm ET marks the final deadline for ovarian cancer victims to vote on Johnson & Johnson's (NYSE: JNJ) $8 billion talcum powder settlement. The plan, with a net present value of $6.475 billion, aims to compensate current and future claimants harmed by J&J's talc products. Ovarian cancer claimants are expected to receive $75,000 to $150,000 each on average.
The Ad Hoc Group of Counsel, representing over 77,500 individuals, urges all affected to vote YES, emphasizing that 75% approval is needed. They refute claims by opposing law firms, stating that the settlement offers a fair and timely resolution compared to prolonged litigation. Claimants can vote at www.OfficialTalcClaims.com or by calling 1-888-431-4056.
Johnson & Johnson (NYSE: JNJ) is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4th at the New York Marriott Marquis. Joaquin Duato, Chairman and CEO, and John Reed, Executive VP of Innovative Medicine R&D, will represent the company in a session scheduled for 10:45 am ET.
A live audio webcast of the session will be available on Johnson & Johnson's investor website. Investors and interested parties can access the webcast at www.investor.jnj.com. An audio replay will be available approximately 48 hours after the event.
Lawyers representing ovarian cancer victims are urging a NO vote on Johnson & Johnson's (NYSE:JNJ) latest $6.5 billion bankruptcy settlement plan. They claim J&J is misleading potential claimants and attempting to secure approvals from individuals without documented ovarian cancer diagnoses. The attorneys argue this strategy could reduce payments to legitimate victims who have incurred losses of $500,000 or more.
The deadline for voting on the bankruptcy proposal is July 26, 2024. Opponents of the plan note that approval would eliminate rights to a jury trial for current and future victims. Since 2016, juries have awarded over $5.4 billion in damages to ovarian cancer claimants, although this amount has been reduced in subsequent court proceedings.
Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking approval of SPRAVATO® (esketamine) as a monotherapy for adults with treatment-resistant depression (TRD). This submission is based on positive results from the Phase 4 TRD4005 study, which showed rapid improvement in depressive symptoms as early as 24 hours after the first dose, sustained through at least 4 weeks of treatment. The safety profile was consistent with existing clinical data.
SPRAVATO® is currently approved in combination with an oral antidepressant for TRD and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. It has been approved in 77 countries and administered to over 100,000 people worldwide. This new application aims to expand its use as a standalone treatment for TRD, potentially offering a new option for patients who have not responded adequately to multiple oral antidepressants.
Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.24 per share for the third quarter of 2024. The dividend will be payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is also set for August 27, 2024. This announcement demonstrates JNJ's commitment to returning value to shareholders through consistent dividend payments.
Johnson & Johnson (NYSE: JNJ) reported strong Q2 2024 results with reported sales growth of 4.3% to $22.4 Billion and adjusted operational growth of 6.5%. The company's EPS decreased by 5.9% to $1.93 due to one-time special charges, while adjusted EPS increased by 10.2% to $2.82.
Key highlights include:
- Robust pipeline progress with TREMFYA, RYBREVANT, and VARIPULSE
- Increased full-year 2024 operational sales guidance reflecting Shockwave Medical acquisition
- Updated full-year 2024 adjusted operational EPS guidance
- Strong performance in Innovative Medicine and MedTech segments
The company's focus on medical innovation and strategic acquisitions positions it for continued growth.
Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, for $1.25 billion. This acquisition secures JNJ the global rights to NM26, a novel, investigational bispecific antibody targeting IL-4Rα and IL-31 pathways in atopic dermatitis (AD). NM26 is ready for Phase 2 clinical trials and aims to provide better treatment for AD by addressing multiple disease-driving pathways. The investment aligns with JNJ's mission to improve care for immune-mediated diseases.
Johnson & Johnson (NYSE: JNJ) announced positive results from an interim analysis of the Phase 3 CARTITUDE-4 study, which evaluated CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) against standard therapies for treating multiple myeloma in patients who have had one prior line of therapy. The study showed that CARVYKTI® achieved a statistically significant and clinically meaningful improvement in overall survival (OS) compared to standard treatments like PVd and DPd. The safety profile was consistent with the approved label. These results will be shared at an upcoming medical meeting and submitted to regulatory authorities.
Johnson & Johnson announced positive results from the Phase 3 Vivacity-MG3 trial of nipocalimab in patients with generalized myasthenia gravis (gMG). The study showed that patients treated with nipocalimab plus standard of care (SOC) improved significantly more than those on placebo plus SOC in the MG-ADL score over 24 weeks. The trial included a broad range of gMG patients, representing 95% of the population. Key secondary endpoints, including muscle strength and function, also showed significant improvements. Safety and tolerability were consistent with prior studies. These findings will be presented at the EAN 2024 Congress and submitted to regulatory authorities.
FAQ
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
